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Background Pulmonary hypertension is a progressive heterogeneous syndrome, characterized by 
elevated pulmonary arterial pressure which can lead to right ventricular failure. Although the 
presence of elevated pulmonary arterial systolic pressure (PASP) in patients with a lung disease is a 
well-known occurrence, little is known about the association between pulmonary function and PASP 
in the general population. We hypothesized that pulmonary function and PASP are associated, 
irrespective of airflow limitation. 
Methods This study was performed within the Rotterdam Study, a prospective population-based 
cohort. We included 1,660 participants with spirometry, performed and interpreted according to 
ATS/ERS-guidelines, and echocardiography performed according to the ASE/EAE/CSE-guidelines. We 
analyzed the association of Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), 
FEV1/FVC and diffusion capacity (DLCO) with estimated PASP (ePASP). Furthermore, we investigated 
the association between spirometry measures, COPD, and echocardiographic pulmonary 
hypertension. 
Results A 10% absolute decrease in FEV1 was associated with an ePASP increase of 0.46 mmHg 
(95%CI: 0.31; 0.61). Similarly, per absolute 10% decrease, FVC was significantly associated with an 
increased ePASP of 0.42 mmHg (95%CI: 0.25; 0.59). FEV1/FVC showed an association of 1.01 mmHg 
(95%CI: 0.58; 1.45) increase in ePASP per 10% absolute decrease. A decrease in DLCO (in mL/min/kPa) 
was associated with an increased ePASP (0.46 mmHg, 95%CI: 0.17; 0.76). We found significant 
associations for FEV1 and FVC with echocardiographic pulmonary hypertension. Importantly, an 
increased ePASP was significantly associated with mortality (Hazard Ratio: 1.042 per mmHg [95%CI: 
1.023-1.062; p<0.001]).  
Conclusion We observed a clearly graded association between pulmonary function and ePASP and 
pulmonary hypertension, even in individuals without airflow limitation.
 Introduction 
Pulmonary hypertension is a progressive and in some cases fatal heterogeneous syndrome, 
characterized by elevated pulmonary arterial pressure and can lead to right ventricular failure [1]. 
Lung diseases and/or hypoxemia are important causes of pulmonary hypertension. Pulmonary 
hypertension is a common co-morbidity of lung disease, with a prevalence of up to 60% in patients 
with chronic obstructive pulmonary disease (COPD)[2]. Pulmonary hypertension in patients with 
COPD seems influenced by two mechanisms, obliteration of the vascular bed and hypoxia-induced 
vasoconstriction [3]. Its presence is associated with a progressive course of disease and decreased 
survival in comparison to patients with COPD without pulmonary hypertension [4]. Although the 
presence of elevated pulmonary arterial systolic pressure (PASP) in patients with lung disease is a 
well-known phenomenon, the relation between pulmonary function and PASP in the general 
population without lung disease is unclear.  
 
We hypothesized that a decrease in lung function, as measured by spirometry and diffusion capacity, 
is associated with an increase in PASP, as measured by echocardiography, in the general population. 
Furthermore, we evaluated the association of ePASP with all-cause mortality.  
Methods 
This study was performed in the first cohort of the Rotterdam Study, an ongoing prospective 
population-based cohort study which started in 1990 in Ommoord, a suburb of Rotterdam. Main 
objectives and methods of the Rotterdam Study have been described elsewhere [5]. The Rotterdam 
Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of 
Health, Welfare and Sport of the Netherlands, implementing the “Wet Bevolkingsonderzoek: ERGO 
(Population Screening Act: Rotterdam Study)”. All participants provided written informed consent to 
participate in the study and to obtain information from their treating physicians. The cohort consists 
of 7,983 participants, aged 55 years and older. At baseline, all participants were visited at home for a 
standardized interview, and underwent a wide array of examinations at the research center. These 
study rounds are repeated every 3-5 years. Participants are actively followed for the occurrence of 
clinical events and mortality as detailed previously [6]. All prescriptions dispensed to the participants 
are collected by linkage to the seven pharmacies covering the study area.  
 
Study population 
The study population consisted of all participants of the Rotterdam Study who underwent both 
spirometry and echocardiography. These were gathered during the fifth study round (2009-2011).  
 
Echocardiography  
Echocardiographs were made using a commercially available ultrasonography system (Vivid I, GE 
Healthcare, Little Chalfont, UK), with a 2.5 MHz transducer according to a standardized protocol. 
Extensive left- and right-sided measurements and measures of both systolic and diastolic function 
were obtained. All images obtained at echocardiography were digitally stored and assessed offline by 
experienced echocardiographists. ePASP (in mmHg) was calculated following the recommendations 
by the ASE/EAE/CSE as the sum of the estimated right atrial pressure (based on the diameter of the 
inferior vena cava and forced respiratory collapse) and the pressure gradient over the tricuspid valve. 
The pressure gradient was computed from the highest Doppler tricuspid regurgitation velocity (TRV) 
gathered from several windows using the simplified Bernoulli equation (4v2, where v is TRV in 
m/sec)8. In those with sufficient tricuspid regurgitation to estimate ePASP, a 40-mmHg cut-off was 
set to define echocardiographic pulmonary hypertension. The definition of echocardiography-based 
pulmonary hypertension (ePH) is based on the measurements of TRV (elevated TRV is defined as TRV 
>3 m/sec, corresponding to a ePASP of >40 mmHg) and right ventricular end-diastolic dimension 
(RVEDD; elevated RVEDD is defined as RVEDD >42 mm) [7–10]. If the TRV was too small to measure, 
but a participant had an elevated RVEDD, this was considered to be indicative of PH (Supplementary 
Table 1). We assessed left ventricular (LV) systolic function through LV fractional shortening in the 
parasternal long-axis view using M-mode. LV fractional shortening (%) at the endocardium was 
calculated by: (LV end-diastolic diameter—LV end-systolic diameter) / LV end-diastolic diameter * 
100% [11,12]. 
 
Spirometry and diffusion capacity 
Spirometry and diffusing capacity were performed using a Master Screen® PFT Pro (CareFusion, San 
Diego, CA, USA) by trained paramedical personnel according to the ATS/ERS guidelines [13,14]. Using 
spirometry FEV1, FVC and the ratio of FEV1 over FVC (FEV1/FVC) were measured. For the diffusion 
capacity, we measured the transfer factor using carbon monoxide in milliliters per minute per kilo 
Pascal (mL/min/kPA). Participants were asked to refrain from using any prescribed pulmonary 
medication one day before the center visit and were asked to refrain from smoking. The spirometry 
and diffusion capacity tests were analyzed by two researchers, and verified by a specialist in 
pulmonary medicine. Spirometry procedures that yielded results that did not meet ATS/ERS criteria 
for acceptability and reproducibility were classified as not interpretable [14]. Diffusion capacity 
procedures preferably attempted twice, if only one attempt was made, tests were scored on the 
basis of the quality of the curve. Multiple attempts yielding results that were not reproducible were 
not used in these analyses.  
 
Mortality 
Participants are actively followed for the occurrence of clinical events and mortality as detailed 




For cross-sectional analyses, we used linear and logistic regression. For mortality analyses, we used 
Cox proportional hazards analyses. Information on potential confounders included age, sex, height 
and weight, was gathered at the study in the same round as the spirometry and echocardiography. 
History of pulmonary embolism was determined on the basis of dispensing data of coumarin 
derivatives with pulmonary embolism as treatment indication through specialized monitoring 
centers. Furthermore, echocardiographic measures of systolic and diastolic function were collected, 
as well as use of medication, a history of heart failure, a history of coronary heart disease (i.e. a 
composite of myocardial infarction, percutaneous coronary intervention, and surgical coronary 
artery bypass graft), in order to adjust for left ventricular failure leading to an increased ePASP. 
Confounders were selected on the basis of their biologic plausibility.[6] The covariables were used in 
the final regression model according their influence on the effect estimate and/or statistical 
significance in the regression model. 
 
Results 
Within the Rotterdam Study, a total of 2,903 individuals underwent echocardiography between 
2009-2011 (44% male, mean age 75 years), 1,660 individuals underwent assessment of both 
echocardiography and spirometry (34% male, mean age 76 years). In this dataset, a total of 284 
participants had COPD according to the spirometry-based GOLD definition, of whom none had very 
severe airflow limitation (GOLD Stage IV). Seventy-one participants had a spirometry test suggestive 
of restrictive lung disease, with or without obstruction. In 1,829 participants, tricuspid regurgitation 
could be measured and the ePASP could be estimated in 1,660 individuals. The baseline 
characteristics of these participants are shown in Table 1. In 2,380 individuals, the presence of 
echocardiographic pulmonary hypertension could be assessed according to the algorithm in 
Supplementary Table 1. Using this algorithm, 99 (4.2%) participants had echocardiographic signs of 
pulmonary hypertension. Data on DLCO and ePASP was available in 1,294 participants. Figure 1 shows 
an overview of the selection of participants for the various analyses reported below.  
 
Association of spirometry measures (FEV1, FVC and FEV1/FVC) and diffusion capacity (DLCO) and PASP. 
Using linear regression an absolute 10% decrease in FEV1 was associated with an ePASP increase of 
0.46 mmHg (95%CI: 0.31; 0.61) after adjustment for age, sex, smoking status, pack-years, left 
ventricular fractional shortening, left ventricular mass, E/A-ratio, body mass index (BMI), heart rate, 
and use of cardiovascular drugs (beta-blockers, AT2-receptor antagonists, high ceiling diuretics, and 
digoxin). Similarly, per 10% absolute decrease, FVC was associated with an increased ePASP of 0.42 
mmHg (95%CI: 0.25; 0.59). Lastly, FEV1/FVC showed an association of 1.01 mmHg (95%CI: 0.58; 1.45) 
increase in ePASP per absolute 10% decrease in FEV1/FVC. (Table 2) 
 
A decrease in DLCO was associated with an increase in ePASP of 0.46 mmHg per mL/min/kPa (95% CI: 
0.17; 0.76); this association remained significant after adjustment for age, sex, hemoglobin level, 
smoking status, pack-years, left ventricular mass, E/A-ratio, BMI, heart rate and use of cardiovascular 
drugs (beta-blockers, AT2-receptor antagonists, and digoxin). (Table 2) 
 
As a sensitivity analysis, we excluded participants with COPD and restrictive lung disease defined on 
the basis of spirometry (FEV1/FVC < 0.70; n = 284, restriction n = 71). After this exclusion, the 
associations between the spirometric measures and ePASP persisted. For FEV1 ePASP was associated 
with an increase of 0.36 mmHg (95%CI: 0.15; 0.57) adjusted for age, sex, smoking status, pack-years, 
left ventricular fractional shortening, left ventricular mass, E/A-ratio, body mass index, mean heart 
rate, history of coronary heart disease and use of cardiovascular drugs. For FVC this increase in 
ePASP was 0.32 mmHg (95%CI: 0.11; 0.53). For FEV1/FVC, a non-significant increase in ePASP was 
seen with an effect estimate of 0.62 mmHg (95%CI: -0.13; 1.37). In this subgroup of participants 
without airflow limitation, a decrease in DLCO was associated with a non-significant increase in ePASP 
of 0.17 mmHg (95%CI: -0.17; 0.51, Table 3). 
 
Spirometry and pulmonary hypertension 
When we analyzed pulmonary hypertension dichotomously, FEV1, FVC, and FEV1/FVC were 
significantly associated with an increased risk of pulmonary hypertension, defined by 
echocardiography (Supplementary Table 1). Per 10% decrease, the FEV1 was associated with an 
adjusted odds ratio of pulmonary hypertension of 1.18 (95%CI: 1.04; 1.34). FVC was associated with a 
similar adjusted odds ratio of 1.18 (95%CI: 1.02; 1.36). For FEV1/FVC, the adjusted odds ratio was 
1.30 (95%CI 0.94; 1.79). For DLCO, the adjusted odds ratio was 1.05 (95%CI: 0.84; 1.31). (Table 4). 
 
ePASP and mortality 
Lastly, we analyzed the association between ePASP and all-cause mortality. In 1,652 participants with 
available follow-up data (mean follow-up: 3,44 years; median follow-up: 3,49 years, 180 deaths), an 
increased ePASP was significantly associated with mortality with a hazard ratio (HR) of 1.042 per 
mmHg (95%CI 1.023; 1.062 p<0.001). In participants without COPD (n=1,298), ePASP was significantly 
associated with mortality (hazard ratio: 1.030 per mmHg, 95%CI 1.004; 1.056 p=0.022). In 
participants with COPD (n=284), ePASP was associated with mortality (hazard ratio: 1.037, 95%CI 
1.004; 1.072, p= 0.027). These analyses were adjusted for sex, age and smoking. 
 
Discussion 
In this population-based cohort, we observed that pulmonary function was associated with PASP. In 
this cross-sectional analysis, there were significant associations for FEV1 % predicted, FVC % predicted 
and FEV1/FVC with ePASP as a continuous outcome and pulmonary hypertension as a dichotomous 
outcome, adjusted for clinically relevant confounders. For diffusion capacity, there was a significant 
association for PASP as a continuous variable, but a non-significant association for pulmonary 
hypertension, most likely due to smaller number of cases in this sample. EPASP was predictive of 
mortality at long-term follow-up, even after adjustment for measures of pulmonary function.  
The association of the spirometric measures FEV1, FVC, and FEV1/FVC with ePASP is present in 
individuals without airflow limitation, which is indicative of COPD, or restrictive spirometry. To our 
knowledge this is the first time these associations are shown in the general older population, rather 
than in specifically designed clinic-based studies in patient populations with COPD and/or pulmonary 
hypertension. As demonstrated in the Rotterdam Study and many other prospective cohort studies, 
pulmonary function decreases over time as people age, irrespective of the presence of COPD and 
new reference values have been proposed [15–18]. Thus, the association found in the present study 
may reflect a process of worsening pulmonary function in elderly populations resulting in increasing 
PASP and related to the ageing process or the accumulation of deleterious exposures and damage 
with age. Our study might provide insight in the mechanisms of increasing PASP in a large, and 
otherwise relatively healthy, general population. Previously, Grossman and colleagues could not 
demonstrate an association between spirometry and ePASP; this was however in a population of 
young healthy males.[19] 
 
Previously, Choudhary e.a. reported associations of both obstructive and restrictive spirometric 
measures with pulmonary hypertension in African-Americans [20]. Our results indicate that an 
impaired lung function, even within the normal spectrum, is associated with higher pulmonary 
arterial pressures. This is relevant for the life expectancy of the affected individuals. We showed a 
significant association between ePASP and an increased risk of all-cause mortality in this population-
based study. This is in line with previous results in an aging population [21].  
 
Limitations and strengths 
 A major limitation in this study is that we are not able to employ the gold standard for the diagnosis 
of pulmonary hypertension, which is right-heart catheterization. We were, however, quite 
conservative with respect to the definition of pulmonary hypertension based on echocardiography, 
which would more likely lead to an underestimation of the prevalence of pulmonary hypertension 
[10]. Also, ePASP has been shown to correlate will with invasively measured pulmonary arterial 
pressure, especially within the normal range of pulmonary arterial pressures, which most of the 
Rotterdam Study participants had [22–24]. Another limitation, due to the cross-sectional design of 
the study, is that it is difficult to disentangle cause and consequence and further longitudinal studies 
are required to clarify causality. With our sensitivity analysis, we showed effects across the full 
spectrum of lung function measures, independent of obstructive lung disease (the most prevalent 
cause of pulmonary hypertension in group 3 of the WHO Classification of pulmonary hypertension), 
showing that our primary associations are not driven by those participants with severely impaired 
lung function. Also, the prognostic implications of these slight elevations in ePASP due to reductions 
in pulmonary function and diffusion capacity remain to be determined. A recent study in patients 
with idiopathic pulmonary fibrosis showed an estimated yearly increase of PASP of 1.8 mmHg during 
a short follow-up [25]. This is markedly higher than the effects we report, but the participants in our 
study differ greatly from patients with idiopathic pulmonary fibrosis. Our data are derived from a 
general (aging) population, whereas the previous study included participants with a clear underlying 
lung disease. The mechanisms underlying increasing PASP in both groups may strongly differ. Lastly, 
we were able to show an increased risk of mortality with increasing ePASP, but further exploration of 
the mechanisms underlying these findings is needed.  
 
The strengths of the study are the prospectively gathered population-based data, which reduces the 
risk of selection bias. Furthermore, we had a wide range of detailed information in this large group of 
older participants available (including follow-up for mortality) and, especially with respect to PH and 
lung function (encompassing spirometry and diffusion capacity), population-based data are scarce. 
 
Conclusion 
We show an association of pulmonary function and diffusion capacity with PASP in a general 
population. Furthermore, the spirometric measures FEV1 and FVC are associated with an increased 
risk of pulmonary hypertension. Lastly, we showed a markedly increased risk of mortality with 
increasing ePASP. The immediate clinical implications of these findings remain to be explored, but 
may be important in the development of new screening and diagnostic algorithms and the 
understanding of the biological processes leading to pulmonary hypertension.  
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 Characteristics  Total 
Sex N (%) Male 605 (34.4 %) 
Female 1055 (63.6 %) 
Age Years (SD)  75.7 (6.3) 
Height cm (SD)  165.9 (9.0) 
Smoking Status† N (%) Never  612 (36.9 %) 
Past 877 (52.8 %) 
Current 142 (8.6 %) 
Pack Years mean (SD)  21 (21) 
Blood Pressure mmHg (SD) Systolic 151 (22) 
Diastolic 85 (11) 
BMI  kg/m2 (SD)  26.9 (4.0) 
Echocardiography ePASP mmHg (SD) 26.1 (6.9) 
LV mass grams (SD) 129.6 (38.1) 
LVEDD mm (SD) 51.1 (5.1) 
Fractional Shortening % (SD) 41.5 (5.7) 
E/A Ratio (SD) 0.90 (0.35) 
Echographic Pulmonary Hypertension* N (%)  99 (4.2 %) 
History of Coronary Heart Disease** N (%)  336 (11.6 %) 
History of Heart Failure N (%)  63 (3.8 %) 
Pulmonary embolism N (%)  18 (1.1 %) 
Pulmonary Function FEV1 L (SD) 2.29 (0.66) 
FEV1 percent predicted % (SD) 104 (22) 
FVC L (SD) 3.02 (0.83) 
FVC percent predicted % (SD) 109 (20) 
FEV1/FVC % (SD) 76 (8) 
 DLCO mL/min/kPa§ 7.13 (1.45) 
GOLD Classification¶, N (%) No obstruction ‡ 1305 (78.6) 
I 139 (8.4 %) 
II 125 (7.5 %) 
III 20 (1.2 %) 
 IV 0 (0%) 
Table 1. Baseline characteristics of the 
study population (n=1,660) 
BMI: Body Mass Index, ePASP = estimated 
Pulmonary Artery Systolic Pressure, LV = left 
ventricular, LVEDD = Left ventricular end 
diastolic dimension, E/A-ratio: ratio of early and 
late transmitral left ventricular filling velocity, 
SD: Standard Deviation.† Smoking status 
missing: n=29.* Based on Tricuspid valve 
Regurgitation Velocity and ePASP and/or secondary signs of PH such as Right Ventricle End Diastolic Dimension, total sample = 2380. ** Myocardial infarction, Coronary 




Spirometry suggestive of restriction  71 (4.3 % 
Medication use Angiotension-2 Antagonist (%) 166 (10.0 %) 
 Beta-blocking agents (%) 369 (22.2 %) 
 Digoxin (%) 23 (1.4 %) 
 High Ceiling diuretics (%) 76 (4.6 %) 
 Table 2. Effect estimates of pulmonary function measures on ePASP in mmHg 
 
* per 10% decrease, n=1,660 
**per decrease in mL/min/kPa, n=1,294 
‡ For FEV1, FVC and FEV1/FVC the analyses were 
adjusted for: sex, age, smoking status, pack-
years, left ventricular fractional shortening, left 
ventricular mass, E/A ratio, BMI, heart rate, use 
of beta-blocking agents, use of AT2-receptor 
antagonists, use of high ceiling diuretics, and 
use of digoxin.  
For DLCO the analyses were adjusted for: sex, 
age, haemoglobin level, smoking status, pack-years, left ventricular fractional shortening, left ventricular mass, E/A ratio, BMI, heart rate, use of beta-blocking agents, use 
of AT2-receptor antagonists, and use of digoxin. 
 
 
Table 3. Effect estimates of pulmonary function measures on ePASP in mmHg, excluding participants with COPD or restriction 




FEV1 % predicted* 0.60  0.45; 0.75 0.46 0.31; 0.61  <0.0001 
FVC % predicted * 0.62 0.46; 0.78  0.42 0.25; 0.59 <0.0001 
FEV1/FVC* 1.04 0.62; 1.47 1.01 0.58; 1.45 <0.0001 
DLCO** 
 
0.44 0.19; 0.69 0.46 0.17; 0.76    0.002 




FEV1 % predicted* 0.49 0.29; 0.70 0.36 0.15; 0.57 0.001 
 * per 10% decrease, n=1,305 
**per decrease in mL/min/kPa, n=1,035 
‡ For FEV1, FVC and FEV1/FVC the analyses were 
adjusted for: sex, age, smoking status, pack-years, left ventricular fractional shortening, left ventricular mass, E/A ratio, BMI, heart rate, history of coronary heart disease, 
use of beta-blocking agents, use of AT2-receptor antagonists, use of high ceiling diuretics, and use of digoxin.  
For DLCO the analyses were adjusted for: sex, age, smoking status, pack-years, left ventricular fractional shortening, left ventricular mass, E/A ratio, BMI, heart rate, history 
of coronary heart disease, use of beta-blocking agents, use of AT2-receptor antagonists, and use of digoxin. 
 




‡ Adjusted for: sex, age, smoking status, pack-
years, left ventricular fractional shortening, left 
ventricular mass, E/A ratio, BMI, heart rate, use 
of beta-blocking agents, use of AT2-receptor 
antagonists, use of high ceiling diuretics, and 




FVC % predicted * 0.51 0.31; 0.71 0.32 0.11; 0.53 0.003 
FEV1/FVC* 0.73 -0.03; 1.48 0.62 -0.13; 1.37 0.106 
DLCO** 0.13 -0.14; 0.40 0.17 -0.17; 0.51 0.321 






FEV1 % predicted* 1.26 1.15; 1.38 1.16 1.02; 1.31 0.021 
FVC % predicted*  1.33 1.20; 1.48 1.17 1.01; 1.35 0.034 
FEV1/FVC* 1.27 1.01; 1.59 1.27 0.92; 1.77 0.149 
DLCO** mL/min/kPa 1.09 0.93; 1.28 1.05 0.84; 1.32 0.650 
 Supplementary table 1. Definition of pulmonary hypertension based on echocardiography (ePH)1 





PASP =< 40 
mmHg 
TRV elevated, 
corresponding to PASP 
> 40 mmHg 
RVEDD missing Missing No ePH No ePH ePH 
RVEDD normal Missing No ePH No ePH ePH 
RVEDD elevated ePH ePH ePH ePH 
RVEDD: Right ventricle end diastolic diameter, TRV: Tricuspid valve regurgitation velocity, PASP: Pulmonary artery systolic pressure.  
1.  Moreira EM, Gall H, Leening MJG, et al. Prevalence of pulmonary hypertension in the general population: The Rotterdam Study. PLoS One 2015;10(6):e0130072.  
 
 
 
 
 
 
 
 
  
 
 
